|
| | 
|
 | |
        
|  |
 
|
 Biogen Idec Inc. - [Ticker: BIIB] |     | | Last Trade | 315.51 | Last Trade Time | 2017-11-01 - 19:35:00 | | Variation | +3.85 (+1.24%) | Open | 312.75 | | High | 319.95 | Low | 311.57 | | Volume | 1,047,609 | Average Volume (3m) | 0 | | Yield | | Bid / Ask | 315.47 x 300 - 315.59 x 200 | | Former Close | 311.66 | 52 Week Range | [0.00 - 0.00] | | PER | 0.00% | EPS | 0.00 | | Ex-Dividend Date | | Dividend Payment | | | Market Capitalization | 0 | 1 Year Price-Target | 0.00 | | Note: The data may have some minutes of delay. |
| | Watch more quotes |
| Last 10 Forum Topics about Biogen Idec Inc.: | | No topics about Biogen Idec Inc. [BIIB] have been found, but a search on the Forum for more topics related to Biogen Idec Inc. is advised. |
|
News about Biogen Idec Inc. [BIIB]: (ordered by relevance)
| | Biogen Alzheimer's Drug Shows Brain Swelling In 35% Of Patients Benzinga
Where Biogen Stands With Analysts - Benzinga Benzinga
Is Biogen Inc (BIIB) a Stock to Watch After Losing -3.00% This Week? InvestorsObserver
Biogen (BIIB) Stock Rises After Reporting Positive Data in Phase 3 Alzheimer's Trial InvestorsObserver
Will Biogen Stock Rise After The Recent 6% Fall? Forbes
Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst - Benzinga Benzinga
Biogen Stock To See Much Higher Levels After A 38% Rise Yesterday Forbes
UPDATE: Biogen Shares Halted Ahead Of FDA Decision On Co.'s Alzheimer's Candidate, Aducanumab Monday Benzinga
Here?s Why Biogen Stock Can Offer Over 35% Gains Forbes
Biogen Alzheimer's Drug Wins Historic Approval, but FDA Requires New Trial Genetic Engineering & Biotechnology News
Biogen Drops Idec From Name Wall Street Journal
Biogen Idec Becomes Biogen Business Wire
Biogen Inc. Common Stock (BIIB) Stock Price, Quote, News & History Nasdaq
Biogen Stock: With Alzheimer's Treatment In FDA Court, Is BIIB Stock A Buy In January 2021? Investor's Business Daily
Bleeding Disorders Treatment Market Generic Products To Be The Growth Factor For This Market Medgadget
Biogen pushes back against critics of Alzheimer's drug as early sales hit $2mln ZAWYA
Biogen bats aside Aduhelm jitters with confident third quarter The Pharma Letter
Biogen Idec: A Great Company, But Not An Alpha Opportunity Seeking Alpha
Biogen/Samsung Approval of BYOOVIZ? | Goodwin - JDSupra JD Supra
Biogen launches new trial of Alzheimer's drug aducanumab McKnight's Long Term Care News
Biogen Idec Stock Hits New 52-Week High (BIIB) TheStreet.com
Biogen Alzheimer's drug in doubt after criticism from expert panel Financial Times
Cipla receives final approval for generic version of Biogen IDEC Inc.'s Tecfidera® (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack) PRNewswire
Baidu And Nvidia Lead The QQQ Lower Thursday - Benzinga Benzinga
Biogen Idec (NASDAQ: BIIB) will add 100 workers in North Carolina's Research Triangle Park Triangle Business Journal
Biogen Idec's Plegridy approved in Europe for relapsing-remitting multiple sclerosis The Pharma Letter
Biogen Inc. (BIIB) Stock Price Today, Quote & News Seeking Alpha
Biogen Idec's Strategy For Neurology RD Success Life Science Leader Magazine
Biogen Analysts Laud FDA Extension of Alzheimer's Drug Review TheStreet
Is Biogen Getting Desperate? Motley Fool
Biogen Idec (BIIB) shifts Machelle Sanders from head of RTP manufacturing to lead multiple sclerosis development - Triangle Business Journal Triangle Business Journal
Subcutaneous Biologics Market Market to See Huge Growth by 2030 | Abbott Laboratories, Pfizer Inc., Genentech Inc., Novartis AG, Biogen Idec Medgadget
FDA Accepts Biogen's BLA for Alzheimer's Candidate Aducanumab Genetic Engineering & Biotechnology News
Which Fund Has The Most To Gain From Biogen Idec? Benzinga
Biogen Idec to Acquire Stromedix Business Wire
Biogen Agrees to Pay $22 Million to Resolve Allegations that it Paid Kickbacks Through Two Co-Pay Foundations Department of Justice
Biogen Idec provides coach commuting for suburban workers Boston Globe
Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix FierceBiotech
Biogen Idec Moves Aggressively, Advances Alzheimer Drug InTo Phase 3 Clinical Leader
Biogen Idec grabs Convergence, neuropathic pain portfolio in $675M buyout FierceBiotech
Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership Business Wire
Biogen Idec Moving HQ Back to Cambridge, Constructing Two New Buildings at Kendall Square Xconomy
Biogen Idec sets price for new MS pill Boston Globe
How Biogen Makes Money: Treatments for Neurological Disorders Investopedia
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe Business Wire
Biogen Idec Trading Higher on 1.7x Above-Average Volume (BIIB) - Benzinga Benzinga
Profits up, Biogen cuts 11% of global workforce Fortune
Exclusive: Biogen prices hemophilia drug on par with older therapies Reuters
Biogen Idec Set to Join the S&P 100; Keurig Green Mountain to Join the S&P 500; Changes to the S&P MidCap 400 and the S&P SmallCap 600 PR Newswire
UPDATED: Germany gives an initial 'no additional benefit' on Biogen Idec's Tecfidera FiercePharma
In dramatic turn, Biogen seeks FDA approval for experimental Alzheimer's drug ABC News
Biogen Idec, Atlas Venture Pump $17M into Ataxion Genetic Engineering News
ACADIA Pharma Shares Spike ~$0.90 Over Last Min, Now Pulling Back From Session Highs; Traders Circulating Chatter Of Biogen Interest Benzinga
Biogen Idec. chief executive to retire - The Boston Globe Boston Globe
Biogen Idec CEO Jim Mullen Stepping Down, After Tumultuous Year of Shareholder Activism Xconomy
Biogen to pay Forward Pharma $1.25 billion to protect MS drug Reuters
Biogen CEO has 'mixed emotions' as he leaves company after 6 years CNBC
Classen Immunotherapies, Inc. v. Biogen IDEC (Fed. Cir. 2011) Patent Docs
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response - Benzinga Benzinga
Ataxion Announces $17M Series A Financing from Atlas Venture and Biogen Idec Business Wire
Biogen Must Face FCA Suit Minus 17 State-Level Claims Law360
Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder Xconomy
| For more news about Biogen Idec Inc. click here:
Biogen Idec Inc. News |
|
Website Width:
Background image: |
|  | |
|
|
![Biogen Idec Inc. - [Ticker: BIIB] chart](http://www.tr4der.com/chart/tr4der-BIIB-1-year.png)
